Price alert —
Sign in to get a one-time email the moment ADMA crosses your price. Free accounts included.
Sign in / create a free accountADMA Biologics Inc is a healthcare company listed in the US.
ADMA last traded at $8.38, down 2.4% on the day; that's in the lower part of its 52-week range ($7.21–$18.00). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A quick snapshot built from the data on this page — not investment advice. Always do your own research.
Our cash-flow model pegs fair value near $-171.80 (fair range $-172–$12). The model's verdict is “Unknown” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 806.42 (antifragile)
- ✓ Current ratio 6.71 (antifragile)
- ✓ Debt/equity 0.31 (antifragile)
- ✓ Goodwill 1% of assets (organic growth)
- ⚠ Debt exceeds cash
- ⚠ Negative retained earnings
- ⚠ Receivables growing faster than revenue
Price implies ~77% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
ADMA is a $2.0 billion company, priced at 13× last year's earnings, and the stock is trading near the bottom of its 52-week range.